• 内刊赠阅
  • |
  • 免费通道
  • |
  • 行业内参
  • |
  • 帮助中心
  • |
  • 关于我们
  • |
注 册
中国 +86
  • +123
  • +125
  • +666
  • +666
  • +555555
  • +666
  • +666
  • +666
请输入真实手机号
请输入图片验证码
请输入短信验证码
请输入密码

已有账号,

忘记密码
中国 +86
  • +123
  • +125
  • +666
  • +666
  • +555555
  • +666
  • +666
  • +666
请输入真实手机号
请输入图片验证码
请输入短信验证码
请输入新密码

已有账号,

关于“互联网招聘”的报告

本报告研究涉及企业/品牌包括:智联招聘、前程无忧、58同城、赶集网、猎聘、拉勾、脉脉、大街、BOSS直聘、斗米、兼职猫、猎聘同道、招财猫直聘、店长直聘、中华英才网、赶集网、领英、应届生求职网、脉脉、智通人才

产业变革、技术升级、政策扶持以及90后用户人群的崛起,其对招聘体验提出了更高要求,驱动了互联网招聘行业的发展。iiMedia Research(艾媒咨询)数据显示,2018年中国互联网招聘用户规模接近2亿,近八成求职者偏好利用多个网络招聘平台来拓宽应聘渠道,但各个主流招聘平台呈现出差异化发展趋势。综合招聘平台依然是求职者的首选,成功率是求职者选择网络招聘平台的首要因素,而企业信息不真实成为求职者最介意因素。未来,互联网招聘平台将更趋向专业化、精细化,向技能培训延申, 盈利模式将加速向C端拓展,AI在其中将扮演重要角色。

 The industry reform, technology upgrading, policy support and the rise of the post-90s user group put forward higher requirements for the recruitment experience, driving the development of the Internet recruitment industry. According to data from iiMedia Research, in 2018, the number of Internet recruitment users in China is nearly 200 million, and nearly 80% of job seekers prefer to use multiple online recruitment platforms to broaden the recruitment channels. However, each mainstream recruitment platform shows the trend of alienated business trip development. General recruitment platform is still the first choice for job seekers, the success rate is the first factor for job seekers to choose online recruitment platform, while the unreal enterprise information becomes the most important concern for job seekers. In the future, the Internet recruitment platform will be more professional and refined, extending to skill training, and the profit model will be accelerated to expand to the c-end, in which AI will play an important role.

本报告研究涉及企业/品牌包括:智联招聘、前程无忧、58同城、赶集网、拉勾网、脉脉、大街、BOSS直聘、斗米、兼职猫、招财猫直聘、店长直聘、中华英才网、领英、应届生求职网、智通人才

iiMedia Research(艾媒咨询)监测发现,猎聘同道的月活跃用户量为154.91万,在艾媒北极星求职招聘APP中排名第六,在垂直招聘类APP排名中继续稳坐首席,猎聘同道的成功,很大程度得益于其较为强大的猎头服务和较为精准的市场定位。然而,随着招聘行业逐渐进入成熟阶段,各大求职招聘类APP的用户渗透率总体平稳;新形势下,对于求职招聘类APP而言,深耕市场,提高服务或许才是唯一的出路。

The scale of China's bio-pharmaceutical industry continues to grow, and the proportion of bio-pharmaceutical output in the pharmaceutical industry continues to rise. In 2017, the total output value of the bio-pharmaceutical industry in China's park was about 1.5 trillion yuan. At present, China's biomedical industry has formed three major clusters, including the Bohai Rim region, the Yangtze River Delta region and the Pearl River Delta region, and the industrial agglomeration effect is outstanding. China's bio-pharmaceutical industry is in a stage of rapid development. In 2018, many head-to-head listed companies in biomedical related fields such as monoclonal antibodies, blood products and vaccines all exceeded 100 million yuan, achieving year-on-year growth. According to iiMedia Research, netizens in Shanghai are most concerned about the biomedical industry, and 40.9% of netizens surveyed support the application of transgenic technology in the pharmaceutical field. Among the heads of monoclonal antibodies, blood products and vaccines, Fuhong Hanlin as well as Weiguang Bio and Lidmanthe has the best online reputation,iiMedia Consulting analysts believe that in the future, the combination of artificial intelligence with new drug research and the fierce competition among head enterprises is an important trend in the development of China's biomedical industry.

没找到想要的报告?

没有你想要的报告?立即告诉我们!

提交报告反馈

在线
客服